Proximagen
Company

Last deal

$16.M

Amount

Venture - Series Unknown

Stage

29.09.2011

Date

2

all rounds

$96.5M

Total amount

General

About Company
Proximagen is developing drugs for neurodegenerative disorders.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2003

Number of employees

Company Type

For Profit

Last funding type

Venture - Series Unknown

IPO status

Private

Description

The company specializes in the development of novel therapeutics for the treatment of central nervous system diseases, offering drug development and commercialization services through medicinal chemistry, biology, drug metabolism, and pharmacokinetics capabilities.
Contacts